Published: 2 December 2020
Author(s): Maurizio Giuseppe Abrignani, Luigi Gatta, Domenico Gabrielli, Giuseppe Milazzo, Vincenzo De Francesco, Leonardo De Luca, Maura Francese, Massimo Imazio, Elisabetta Riccio, Roberta Rossini, Fortunato Scotto di Uccio, Marco Soncini, Angelo Zullo, Furio Colivicchi, Andrea Di Lenarda, Michele Massimo Gulizia, Fabio Monica
Issue: April 2021
Section: Review article

Aspirin and P2Y12 receptor antagonists are widely used across the spectrum of cardiovascular and cerebrovascular diseases. Gastrointestinal complications, including ulcer and bleeding, are relatively common during antiplatelet treatment and, therefore, concomitant proton pump inhibitor (PPI) treatment is often prescribed. However, potential increased risk of cardiovascular events has been suggested for PPIs, and, in recent years, it has been discussed whether these drugs may reduce the cardiovascular protection by aspirin and, even more so, clopidogrel.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.